Indication
Ankylosing spondylitis
Ankylosing spondylitis is a chronic, systemic inflammatory arthritis classified within the spondyloarthritis family that primarily targets the axial skeleton, particularly the sacroiliac joints and spine. Read more about Ankylosing spondylitis
715 drugs 254 manufacturers
Drugs that treat it
Common Ankylosing spondylitis therapies.
COSENTYX (secukinumab)
METHYLPREDNISOLONE
PREDNISONE
XELJANZ XR (tofacitinib citrate)
TRIAMCINOLONE ACETONIDE
NAPROXEN SODIUM
PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE SODIUM PHOSPHATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAnkylosing spondylitis is a chronic, systemic inflammatory arthritis classified within the spondyloarthritis family that primarily targets the axial skeleton, particularly the sacroiliac joints and spine.
The condition characteristically manifests in late adolescence or early adulthood, exhibiting a strong genetic association with human leukocyte antigen B27 (HLA-B27).
Pathophysiologically driven by immune-mediated enthesitis and osteitis, it causes inflammatory back pain, progressive spinal stiffness, and peripheral joint involvement.
Over time, persistent chronic inflammation can stimulate pathologic new bone formation, syndesmophyte bridging, and eventual spinal ankylosis, leading to marked loss of mobility and structural postural changes.
- nih.gov
Ankylosing spondylitis is a chronic, systemic inflammatory arthritis classified within the spondyloarthritis family that primarily targets the axial skeleton, particularly the sacroiliac joints and spine Pathophysiologically driven by immune-mediated enthesitis and osteitis, it causes inflammatory back pain, progressive spinal stiffness, and peripheral joint involvement Over time, persistent chronic inflammation can stimulate pathologic new bone formation, syndesmophyte bridging, and eventual sp...
- medlineplus.gov
Ankylosing spondylitis is a chronic, systemic inflammatory arthritis classified within the spondyloarthritis family that primarily targets the axial skeleton, particularly the sacroiliac joints and spine Pathophysiologically driven by immune-mediated enthesitis and osteitis, it causes inflammatory back pain, progressive spinal stiffness, and peripheral joint involvement
Personalize your experience
Follow Ankylosing spondylitis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.